Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1‐antihistamine treatment: results of the phase IV open‐label SUNRISE study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1‐antihistamine treatment: results of the phase IV open‐label SUNRISE study

Published:2018-09-17 Issue:1 Volume:180 Page:56-66
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Bérard F.¹,Ferrier Le Bouedec M.C.²,Bouillet L.³^ORCID,Reguiai Z.⁴^ORCID,Barbaud A.⁵^ORCID,Cambazard F.⁶,Milpied B.⁷^ORCID,Pelvet B.⁸,Kasujee I.⁹,Gharbi H.⁸,Lacour J.P.¹⁰^ORCID

Affiliation:

1. Clinical Immunology and Allergology CH Lyon‐Sud Claude Bernard University Lyon I France

2. Dermatology Department CHU Clermont‐Ferrand France

3. Department of Internal Medicine Grenoble Alpes University La Tronche France

4. Dermatology Department Clinique Courlancy Reims France

5. Dermatology Department Hospital Tenon Paris France

6. Dermatology Department CHU Saint‐Etienne Saint‐Etienne France

7. Dermatology Department St. Andre Hospital Bordeaux France

8. Novartis Pharma SAS Rueil‐Malmaison France

9. Novartis Pharma AG Basel Switzerland

10. Dermatology Department University Hospital of Nice France

Funder

Novartis Pharma

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.16904

Reference23 articles.

1. Management of chronic spontaneous urticaria: practical parameters;Marzano AV;G Ital Dermatol Venereol,2015

2. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report1

3. Activation of coagulation in chronic urticaria in relation to disease severity and activity

4. Chronic spontaneous urticaria: an autoimmune disease? A revision of the literature

5. Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality of life measurement in assessing treatment effectiveness in urticaria: European experts position statement;International Journal of Dermatology;2024-07-04

2. Quality of life measurement in urticaria: Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient‐Oriented Outcomes and Urticaria and Angioedema;Journal of the European Academy of Dermatology and Venereology;2024-06-10

3. Omalizumab Drug Survival in Chronic Urticaria: A Retrospective Multicentric French Study;The Journal of Allergy and Clinical Immunology: In Practice;2023-12

4. Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status;Dermatology and Therapy;2023-09-30

5. Elevated baseline soluble FcεRI may be linked to early response to omalizumab treatment in chronic spontaneous urticaria;Journal of the European Academy of Dermatology and Venereology;2023-09-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3